| Document |
Document Title |
|
WO/2000/059516A1 |
The present invention relates to improved methods for making and using bioadhesive, bioresorbable, anti-adhesion compositions made of intermacromolecular complexes of carboxyl-containing polysaccharides, polyethers, polyacids, polyalkyle...
|
|
WO/2000/059405A1 |
The present invention provides a lumen support stent for use in an artery or any body lumen. The stent is formed from a plurality of ladder elements having elongated ribs and end rungs affixed to the elongated ribs. The elongated ribs of...
|
|
WO/2000/056377A1 |
Methods of improving the surface characteristics of a medical device or instrument, and the devices and instruments improved thereby, are provided. The disclosed methods involve the chemical attachment of an activated hyaluronic acid, su...
|
|
WO/2000/052052A1 |
The invention relates to novel collagen peptides that are modified by grafting free or substitued thiol functions carried by mercaptoamine radicals. The aim of the invention is to provide thiol collagens that can be cross-linked in a suf...
|
|
WO/2000/050106A2 |
The invention relates to hemocompatible surfaces, characterized in that they contain materials and that components of the outer layer of blood cells and/or mesothelial cells are deposited on and/or introduced into the surface of said mat...
|
|
WO/2000/048645A2 |
An apparatus (20) and method for selectively delivering a medicament to a target location (28) of the wall of a body cavity, blood vessel (26), or the like, comprising a compressed hollow cylinder (40) of permeable, expandable foam, atta...
|
|
WO2000023124A9 |
Multi-functional coatings which are used to cover medical devices that are destined for in vivo use. The multi-functional coating includes multiple layers wherein each layer exhibits a different biological property, such as antimicrobial...
|
|
WO2000009177A9 |
An enhanced antimicrobial antithrombogenic medical device is formed by using an oligodynamic metal and a noble metal with a polymer, and forming the mixture into a device. By using low concentrations of conductive polymers or ionophoric ...
|
|
WO/2000/045162A1 |
Blood coagulation preventing agents containing as the active ingredient an inorganic acid salt of magnesium; and blood collection containers containing an inorganic acid salt of magnesium. Because of being capable of effectively preventi...
|
|
WO/2000/043120A1 |
A polymeric resin is disclosed in the form of beads or particles having a coating thereon which renders the resin blood compatible. The resin comprises divinylbenzene monomer which has a porosity, pore size, and surface area suitable for...
|
|
WO/2000/043052A1 |
An ePTFE vascular graft having a smooth PTFE luminal surface which is substantially non-adhesive to occlusive blood components. Preferably the graft is a longitudinally extruded and expanded ePTFE tube of about 10-30 microns mean fibril ...
|
|
WO/2000/041739A1 |
Compositions comprising an activated polymeric substrate having an acid moiety-containing biomolecule covalently bonded via the acid moiety to the substrate are disclosed. Methods for making such compositions are also provided, including...
|
|
WO/2000/042173A1 |
The present invention relates to DNAzymes which are targeted against mRNA molecules encoding EGR-1 (also known as Egr-1 or NGFI-A). The present invention also relates to compositions including these DNAzymes and to methods of treatment i...
|
|
WO/2000/040619A1 |
The present invention provides an anti-thrombogenic coating composition for blood-contacting surfaces. The coating comprises a covalent complex of from 1 to 30 hydrophobic silyl moieties of formula (I), wherein R¿1? is an C¿1-8? alkyl ...
|
|
WO2000000239A9 |
The present invention provides a biocompatible material, comprising a phospholipid or phospholipid derivative comprising various functional groups having specific chemical properties, which can function as a modular surface design unit t...
|
|
WO/2000/038602A1 |
The present invention relates to methods for treating inflammation in body tissues. More specifically, certain disclosed methods relate to selectively inducing apoptosis in inflammatory immune cells by heating cells for a sufficient time...
|
|
WO/2000/032249A1 |
A prosthesis is formed from a substrate with an associated attraction compound. The attraction compound binds viable precursor cells to the substrate. Thus, the substrate forms a synthetic tissue supporting viable cells once the substrat...
|
|
WO/2000/030696A1 |
A method for sterilising a medical device comprising a hydrophilic coating using radiation said method comprising the steps of bringing the medical device having such coating in contact with an aqueous liquid for wetting the hydrophilic ...
|
|
WO/2000/029043A1 |
The invention concerns a bioactive prosthesis comprising a support coated with a polymer layer with reactive functions, and a bioactive substance fixed on the prosthesis via said reactive functions so as to be gradually released on a sit...
|
|
WO/2000/027889A1 |
A functional chitosan derivative which comprises a chitin/chitosan, which is a natural polysaccharide, and incorporated therein at least one of a saccharide, a photoreactive functional group, an amphipathic group, e.g., a polyoxyalkylene...
|
|
WO2000009672A9 |
This application provides a DNAzyme which specifically cleaves c-myc mRNA, comprising a 15-nucleotide catalytic domain and two binding domains, one binding domain contiguous with the 5' end of the catalytic domain and the other binding d...
|
|
WO/2000/024339A1 |
The invention relates to an anastomotic device for joining one end of a graft vessel to a target vessel at an opening made in the wall thereof. The anastomotic device comprises a tubular body on which an outer flange, which comes into co...
|
|
WO/2000/024412A2 |
The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
|
|
WO/2000/021585A1 |
The present invention includes a co-polymer film which can be applied over a surface of an article to form a continuous surface that is more biocompatible and has a smoother surface morphology than an untreated article. In general the co...
|
|
WO/2000/018328A1 |
A method for selectively bonding layers of polymeric material, especially expanded polytetrafluoroethylene (ePTFE), to create endoluminal vascular devices. In a preferred method the selective bonding is achieved by applying pressure to s...
|
|
WO/2000/016623A1 |
Antifouling agents comprising an affective amount of a compound represented by general structure (1), wherein X represents -OH, -O(aryl), -O(acyl), -O(sulfonyl), -CN, F, Cl, or Br; Y represents O, S, Se, or NR; Z represents optionally su...
|
|
WO/2000/017254A1 |
Polymers and processes for synthesizing the polymers from $g(a),$g(b)-unsaturated lactones, particularly 2(5H)-furanone, and amines with side chains. The polymers are used as hydrogels, as polymers that can bind metals and form complexes...
|
|
WO/2000/016821A1 |
The invention concerns a bicomposite collagen material which is biocompatible, non-toxic and biodegradable in less than one month, characterised in that it comprises solely, or mainly, two closely linked layers forming a film based on a ...
|
|
WO/2000/016820A1 |
A method for fixation of biological tissues, and bioprosthetic devices prepared by such method. The method generally comprises the steps of: A) fixing the tissue; B) treating the tissue with a mixture of i) a denaturant, ii) a surfactant...
|
|
WO/2000/016764A2 |
Small molecule pharmaceuticals for treating sulfate receptor mediated diseases are disclosed.
|
|
WO/2000/016624A1 |
The formation of biofilms on surfaces in health-related environments can be prevented by the use of a compound represented by general structure (1), wherein X represents -OH, -O(aryl), -O(acyl), -O(sulfonyl), -CN, F, Cl, or Br; Y represe...
|
|
WO/2000/016632A2 |
Disclosed are environmentally safe crop protection agents that interfere with the attachment of a broad range of plant pathogens to plant cells surfaces. The crop protection agents contain a compound represented by general structure (1),...
|
|
WO/2000/016817A1 |
Disclosed are a dermal scaffold comprising neutralized chitosan sponge, neutralized chitosan/collagen mixed sponge or neutralized chitosan/collagen mixed sponge containing chitosan fabrics which has excellent wound healing effect by cons...
|
|
WO/2000/013719A1 |
The present invention relates to a composition comprising heparin to be used as a non-thrombogenic surface when in contact with arterial blood flow. It also relates to a device treated on the surface thereof with such a composition.
|
|
WO/2000/013718A1 |
The present invention relates to a process for preparing surface modifications having an improved antithrombogenic activity, whereby the improvement is achieved by treating heparin at elevated temperature or at elevated pH or in contact ...
|
|
WO/2000/012043A1 |
A primary package containing a low molecular weight peptide-based thrombin inhibitors which package is sealed with a rubber stopper or plunger containing bromobutyl rubber.
|
|
WO/2000/012029A1 |
A transmyocardial implant establishes a blood flow path through a myocardium between a heart chamber and a lumen of a coronary vessel residing on an exterior of the heart. The implant (10) includes a coronary portion (12) sized to be rec...
|
|
WO/2000/010622A1 |
A coated implantable medical device (10) includes a structure (12) adpated for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer (16) positioned on one surface o...
|
|
WO/2000/007650A1 |
A sheet of polyurethane film (11) which can be rendered thrombo-resistant according to the teachings of the present invention.
|
|
WO/2000/006651A1 |
An ion complex which comprises a water-insoluble polyion (P) and a water-soluble polyion (A) and which is insoluble in water and soluble in water-containing organic solvents. The ion complex is suitable for use as a coating material to b...
|
|
WO/2000/002596A1 |
The present invention provides a method of stimulating vascularization at a site in a mammal, said method comprising contacting said site with a matrix comprising gelatin and a nitric oxide inhibitor. The gelatin is preferably denatured ...
|
|
WO/2000/002999A2 |
A cell culture medium and hydrogel matrix for long term storage and proliferation of cells is provided. The cell culture medium and hydrogel matrix may include an effective amount of polar amino acids, the polar amino acids selected from...
|
|
WO/2000/001432A1 |
The invention relates to an oxygenator (13) comprising a hydrophobic membrane structure (25, 26, 28) which comes into contact with blood (36) and serves to supply oxygen to and remove carbon dioxide from the blood. The membrane structure...
|
|
WO/1999/067296A1 |
Disclosed are novel polymers derivatized with at least one -SNO group per 1200 atomic mass unit of the polymer. In one embodiment, the $i(S)-nitrosylated polymer has stabilized -$i(S)-nitrosyl groups. In another embodiment the $i(S)-nitr...
|
|
WO/1999/064085A1 |
The invention relates to a new and improved method for producing biocompatible surfaces, more particularly, the surfaces of medical objects such as implants. The invention particularly relates to stents with enhanced properties.
|
|
WO/1999/064086A1 |
An article (e.g., in the form of an implantable medical article) in the form of a support material bearing an intermediate layer consisting of a functional silicone polymer formulation, the intermediate layer having photoimmobilized ther...
|
|
WO/1999/062572A1 |
An intravascular metal stent having a tubular wall and a biocompatible coating on at least a major part of the wall surface which coating has a thickness of less than 4 $g(m)m and contains a diamond like amorphous material, preferably DLN.
|
|
WO/1999/062395A2 |
The present invention is related to a method for preventing the clogging of medicinal drainage or ventilation tubes, comprising coating the surface of said ventilation tubes with anticlogging substances, especially human serum albumin. T...
|
|
WO/1999/061481A1 |
Polysaccharides, which are widely used as anticoagulation drugs, especially heparin, are clinically administered only by intravenous or subcutaneous injection because of their strong hydrophilicity and high negative charge. Amphiphilic h...
|
|
WO/1999/059502A1 |
An implant (10) includes an expandable, flexible membrane (18) mounted over an expandable stent (10), which is releasably affixed to the balloon portion (14) of a catheter (16). The balloon (14) is inflated, thereby enlarging both the st...
|
